Given the correlation of COX-2 in other cancer models, and evidence that regular intake of a COX-2 inhibitor reduces cancer risk [29], future investigations into the mechanisms of KSHV induced COX-2 expression and prostaglandin activity may lead to new treatments for KS patients. The gene discussed is PTGS2; the disease is cancer.